Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Apixaban (ATC: B01AF02)

The subject of this publication is the conclusion of non-exclusive discount contracts pursuant to Section 130a, paragraph 8, SGB V for finished medicinal products with the active substance Apixaban (ATC: B01AF02) within the framework of a so-called "open-house model". With the stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or accession to a discount contract pursuant to Section 130a, paragraph 8, SGB V for the aforementioned active substances or medicinal products. Interested pharmaceutical companies can request the participation documents and the respective contract from the contact address given. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents in full.